Incorrect description of mode of excretion of linagliptin

by Woerle, Hans-Juergen, Patel, Sanjay
Published 2010

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials

by von Eynatten, Maximilian, Gong, Yan, Emser, Angela, Woerle, Hans-Juergen
Published 2013

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

by Johansen, Odd Erik, Neubacher, Dietmar, von Eynatten, Maximilian, Patel, Sanjay, Woerle, Hans-Juergen
Published 2012

The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes

by Woerle, Hans Juergen, Carneiro, Lucianno, Derani, Ayman, Göke, Burkhard, Schirra, Jörg
Published 2012

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

by Groop, Per-Henrik, Cooper, Mark E., Perkovic, Vlado, Emser, Angela, Woerle, Hans-Juergen, von Eynatten, Maximilian
Published 2013

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

by Rosenstock, Julio, Marx, Nikolaus, Neubacher, Dietmar, Seck, Thomas, Patel, Sanjay, Woerle, Hans-Juergen, Johansen, Odd Erik
Published 2015

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials

by Davidson, Jaime A, Lajara, Rosemarie, Aguilar, Richard B, Mattheus, Michaela, Woerle, Hans-Juergen, von Eynatten, Maximilian
Published 2014

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study

by Yki-Järvinen, Hannele, Rosenstock, Julio, Durán-Garcia, Santiago, Pinnetti, Sabine, Bhattacharya, Sudipta, Thiemann, Sandra, Patel, Sanjay, Woerle, Hans-Juergen
Published 2013

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

by McGill, Janet B., Sloan, Lance, Newman, Jennifer, Patel, Sanjay, Sauce, Christophe, von Eynatten, Maximilian, Woerle, Hans-Juergen
Published 2013

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial

by Chen, Yuhong, Ning, Guang, Wang, Changjiang, Gong, Yan, Patel, Sanjay, Zhang, Candice, Izumoto, Toshiyasu, Woerle, Hans-Juergen, Wang, Weiqing
Published 2015

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin

by Zimdahl, Heike, Ittrich, Carina, Graefe-Mody, Ulrike, Boehm, Bernhard O., Mark, Michael, Woerle, Hans-Juergen, Dugi, Klaus A.
Published 2014

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

by Rauch, Thomas, Graefe-Mody, Ulrike, Deacon, Carolyn F., Ring, Arne, Holst, Jens J., Woerle, Hans-Juergen, Dugi, Klaus A., Heise, Tim
Published 2012

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

by Cherney, David ZI, Perkins, Bruce A, Soleymanlou, Nima, Har, Ronnie, Fagan, Nora, Johansen, Odd Erik, Woerle, Hans-Juergen, von Eynatten, Maximilian, Broedl, Uli C
Published 2014

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

by Zinman, Bernard, Inzucchi, Silvio E, Lachin, John M, Wanner, Christoph, Ferrari, Roberto, Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Kempthorne-Rawson, Joan, Newman, Jennifer, Johansen, Odd Erik, Woerle, Hans-Juergen, Broedl, Uli C
Published 2014

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

by Perkins, Bruce A., Cherney, David Z. I., Soleymanlou, Nima, Lee, Justin A., Partridge, Helen, Tschirhart, Holly, Zinman, Bernard, Mazze, Roger, Fagan, Nora, Kaspers, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., Johansen, Odd Erik
Published 2015

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

by Marx, Nikolaus, Rosenstock, Julio, Kahn, Steven E, Zinman, Bernard, Kastelein, John J, Lachin, John M, Espeland, Mark A, Bluhmki, Erich, Mattheus, Michaela, Ryckaert, Bart, Patel, Sanjay, Johansen, Odd Erik, Woerle, Hans-Juergen
Published 2015